These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 33973870)

  • 21. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
    Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
    Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.
    Inoue H; Tamaki Y; Kashihara Y; Muraki S; Kakara M; Hirota T; Ieiri I
    Br J Clin Pharmacol; 2019 Feb; 85(2):393-402. PubMed ID: 30394576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
    Phung OJ; Sobieraj DM; Engel SS; Rajpathak SN
    Diabetes Obes Metab; 2014 May; 16(5):410-7. PubMed ID: 24205921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Krogh J; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Nardini C; Mannucci E
    Diabetes Obes Metab; 2014 May; 16(5):457-66. PubMed ID: 24320621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
    Kim HJ; Noh JH; Moon MK; Choi SH; Ko SH; Rhee EJ; Hur KY; Jeong IK
    J Diabetes Res; 2024; 2024():8915591. PubMed ID: 38223523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients.
    Cao Y; Liang N; Liu T; Fang J; Zhang X
    Endocr Metab Immune Disord Drug Targets; 2023; 23(4):530-547. PubMed ID: 36043731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.